Pneumonia Therapeutics Market Is Predicted To Reach USD 22.9 Billion By 2025: By Grand View Research, Inc.
The global pneumonia therapeutics market is expected to reach
USD 22.9 billion by 2025, according to a new report by Grand View Research,
Inc. This market is anticipated to grow at an unprecedented rate owing to the
increasing prevalence of pneumococcal disease globally. The increasing demand
for pneumonia therapeutics is a result of unmet clinical needs in emerging as
well as developed regions. Increasing focus of healthcare organizations on
raising awareness and issuing guidelines for efficient management of
pneumococcal disease is predicted to broaden the scope for growth over the
coming years.For instance, Infectious Diseases Society of America/American
Thoracic Society has issued guidelines on the management of community-acquired
pneumonia. According to a white paper released by American Academy of Family
Physicians, adherence to these guidelines has resulted in positive patient
outcomes during the treatment of community-acquired bacterial pneumonia in
patients.
Moreover, growing R&D
activities in life sciences are anticipated to create positive impact on the
market over the coming years. Consequentially, increase in number of products,
currently being reviewed under clinical trials, is anticipated to fuel the
overall growth.In the present scenario, there are 12 drugs under investigation
in phase III trials, 4 drugs under phase II, and 3 drugs under phase I trial.
The aforementioned factors exemplify the consistent efforts being made by the
market players. For instance, Omadacycline, a tetracycline under phase III
clinical trial, developed by Paratek Pharmaceuticals is being investigated for
use in the treatment of ventilator-associated and community-acquired bacterial
pneumonia.
U.S. pneumonia therapeutics market by product, 2014 -
2025 (USD Million)
Browse full research report on Pneumonia
Therapeutics Market
Further key findings from the report suggest:
- Vaccines accounted for the largest share in the product segment in 2016. This can be attributed to their high efficacy and growing inclination of patients toward preventive measures
- They are also
expected to grow at a lucrative rate owing to the recommendation by WHO
for their inclusion in national immunization programs
- Drugs are
expected to witness moderate growth rate throughout the forecast period.
This is believed to be a result of the infiltration of generic drugs that
are more cost-efficient.
- North America
accounted fora substantial share in the market owing toincreasing number
of supportive government initiatives and high awareness levels amongst the
end-users
- Asia Pacific
is expected to witness exponential CAGR during the forecast period owing
to its high disease burden and continual infrastructural upgradation of
research & manufacturing facilities in the region
- High
competition has been observed in the market, where major players adopt
strategies such as new product development, collaborations,and strategic
agreements to gain market share
For more information: http://www.grandviewresearch.com
Comments
Post a Comment